NO2014030I1 - (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile ("Rilpivirine") and any therapeutic form thereof as is covered by the relevant patent such as pharmaceutically acceptable salts of Rilpivirie including the hydrochloride salt of Rilpivirine, and emtricitabine. - Google Patents
(E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile ("Rilpivirine") and any therapeutic form thereof as is covered by the relevant patent such as pharmaceutically acceptable salts of Rilpivirie including the hydrochloride salt of Rilpivirine, and emtricitabine.Info
- Publication number
- NO2014030I1 NO2014030I1 NO2014030C NO2014030C NO2014030I1 NO 2014030 I1 NO2014030 I1 NO 2014030I1 NO 2014030 C NO2014030 C NO 2014030C NO 2014030 C NO2014030 C NO 2014030C NO 2014030 I1 NO2014030 I1 NO 2014030I1
- Authority
- NO
- Norway
- Prior art keywords
- rilpivirine
- amino
- rilpivirie
- cyanoethenyl
- emtricitabine
- Prior art date
Links
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 3
- 229960002814 rilpivirine Drugs 0.000 title 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 title 1
- 229960000366 emtricitabine Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49977103P | 2003-09-03 | 2003-09-03 | |
EP03103275 | 2003-09-03 | ||
EP03103319 | 2003-09-08 | ||
EP03103335 | 2003-09-10 | ||
EP03103668 | 2003-10-02 | ||
US50848603P | 2003-10-03 | 2003-10-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO2014030I2 NO2014030I2 (en) | 2014-12-18 |
NO2014030I1 true NO2014030I1 (en) | 2015-01-05 |
Family
ID=34280181
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061374A NO334877B1 (en) | 2003-09-03 | 2006-03-27 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
NO2014030C NO2014030I1 (en) | 2003-09-03 | 2014-12-18 | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile ("Rilpivirine") and any therapeutic form thereof as is covered by the relevant patent such as pharmaceutically acceptable salts of Rilpivirie including the hydrochloride salt of Rilpivirine, and emtricitabine. |
NO2014031C NO2014031I1 (en) | 2003-09-03 | 2014-12-18 | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino-2-pyrimidinyl] amino] benzonitrile (Rilpivirie) and any therapeutically equivalent form thereof protected by the patent concerned such as pharmaceutically acceptable salts of Rilpiverine including the hydrochloride salt of Rilpivirine, and Temofovir disproxil (especially Tenofovir disproxil fumarate salt). |
NO2014032C NO2014032I1 (en) | 2003-09-03 | 2014-12-18 | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenylamino] -2-pyrimidinyl] amino] benzonitrile Rilpivirine) and any therapeutically equivalent form thereof protected of the present patent such as pharmaceutically acceptable salts including the hydrochloride salt of Rilpiverine; tenofovir and especially tenofovir disproxil fumatate and emtricitabine. |
NO2016025C NO2016025I1 (en) | 2003-09-03 | 2016-12-20 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061374A NO334877B1 (en) | 2003-09-03 | 2006-03-27 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2014031C NO2014031I1 (en) | 2003-09-03 | 2014-12-18 | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino-2-pyrimidinyl] amino] benzonitrile (Rilpivirie) and any therapeutically equivalent form thereof protected by the patent concerned such as pharmaceutically acceptable salts of Rilpiverine including the hydrochloride salt of Rilpivirine, and Temofovir disproxil (especially Tenofovir disproxil fumarate salt). |
NO2014032C NO2014032I1 (en) | 2003-09-03 | 2014-12-18 | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenylamino] -2-pyrimidinyl] amino] benzonitrile Rilpivirine) and any therapeutically equivalent form thereof protected of the present patent such as pharmaceutically acceptable salts including the hydrochloride salt of Rilpiverine; tenofovir and especially tenofovir disproxil fumatate and emtricitabine. |
NO2016025C NO2016025I1 (en) | 2003-09-03 | 2016-12-20 |
Country Status (25)
Country | Link |
---|---|
US (9) | US20080200435A1 (en) |
EP (1) | EP1663240B2 (en) |
JP (3) | JP5507791B2 (en) |
KR (1) | KR20060090658A (en) |
CN (1) | CN101060844B (en) |
AP (1) | AP2109A (en) |
AU (5) | AU2004268390B2 (en) |
BE (1) | BE2015C053I2 (en) |
CA (1) | CA2537095C (en) |
CY (5) | CY2015039I1 (en) |
FI (1) | FI1663240T4 (en) |
FR (3) | FR15C0071I2 (en) |
HK (1) | HK1092698A1 (en) |
HR (1) | HRP20150798T4 (en) |
HU (5) | HUS1500052I1 (en) |
IL (2) | IL173438A (en) |
LT (2) | LTPA2016045I1 (en) |
LU (3) | LU92853I2 (en) |
MX (1) | MXPA06002437A (en) |
MY (1) | MY169670A (en) |
NL (2) | NL300781I1 (en) |
NO (5) | NO334877B1 (en) |
NZ (1) | NZ545306A (en) |
PL (1) | PL1663240T5 (en) |
WO (1) | WO2005021001A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (en) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
NZ538611A (en) | 2002-08-09 | 2007-03-30 | Janssen Pharmaceutica Nv | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
JP4922937B2 (en) * | 2004-09-02 | 2012-04-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4-((4-((4- (2-cyanoethenyl) -2,6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile fumarate |
WO2006024668A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
SG155885A1 (en) * | 2004-09-02 | 2009-10-29 | Janssen Pharmaceutica Nv | Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile |
ME01246B (en) * | 2004-09-02 | 2013-06-20 | Janssen Pharmaceutica Nv | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
KR101276571B1 (en) * | 2004-09-02 | 2013-06-18 | 얀센 파마슈티카 엔.브이. | Furamate of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
TWI457136B (en) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Prevention of hiv-infection |
TWI471145B (en) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
RU2008128424A (en) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | PHARMACEUTICAL COMBINATION, INCLUDING NUCLEOTID AND NUCLEOSIDE INVERSORS OF REVERSE TRANSCRIPTASE (SUCH AS TENOFOVIR AND LAMIVUDINES) IN VARIOUS DOSE PARTS |
NZ569347A (en) | 2006-01-20 | 2011-07-29 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
FR2903312B1 (en) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
TWI494133B (en) | 2007-03-14 | 2015-08-01 | Tibotec Pharm Ltd | Powders for reconstitution |
CN102698276B (en) * | 2008-01-03 | 2014-12-10 | 艾克斯-马赛大学 | Bitherapy and tritherapy used for treating an HIV-positive patient |
RU2546529C2 (en) * | 2008-12-24 | 2015-04-10 | Тиботек Фармасьютикалз | Implanted devices for treating hiv |
AU2010338425B2 (en) | 2009-12-21 | 2015-07-23 | Janssen Sciences Ireland Uc | Degradable removable implant for the sustained release of an active compound |
DK3494972T3 (en) | 2010-01-27 | 2024-01-29 | Viiv Healthcare Co | Combinations of dolutegravir and lamivudine for the treatment of HIV infection |
PE20211657A1 (en) * | 2010-11-19 | 2021-08-24 | Gilead Sciences Inc | THERAPEUTIC COMPOSITIONS INCLUDING RILPIVIRIN HCL AND TENOFOVIR DISOPROXIL FUMARATE |
WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
US9233935B2 (en) * | 2011-09-16 | 2016-01-12 | Hetero Research Foundation | Rilpivirine hydrochloride |
PL3067358T3 (en) | 2012-12-21 | 2020-02-28 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NZ741957A (en) | 2015-11-09 | 2019-04-26 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
HRP20240118T1 (en) | 2016-10-24 | 2024-04-12 | Janssen Sciences Ireland Unlimited Company | Dispersible compositions |
US20210128554A1 (en) * | 2016-12-23 | 2021-05-06 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
JP2020517633A (en) * | 2017-04-18 | 2020-06-18 | シプラ・リミテッド | Combination therapy used to treat retroviral infections |
WO2019021319A1 (en) * | 2017-07-27 | 2019-01-31 | Cipla Limited | Pharmaceutical compositions |
WO2021104487A1 (en) | 2019-11-29 | 2021-06-03 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
WO1992001453A1 (en) | 1990-07-19 | 1992-02-06 | Otsuka Pharmaceutical Co., Ltd. | Solid preparation |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
ATE184787T1 (en) | 1992-05-13 | 1999-10-15 | Wellcome Found | THERAPEUTIC COMBINATIONS |
JPH06316524A (en) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | Anti-aids virus agent |
TW401303B (en) * | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
IT1281502B1 (en) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN COMBINATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
ES2241663T3 (en) | 1999-09-21 | 2005-11-01 | Skyepharma Canada Inc. | SUPERFICIALLY MODIFIED PARTICULATED COMPOSITIONS OF BIOLOGICALLY ACTIVE SUBSTANCES. |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
TWI284048B (en) | 2000-01-27 | 2007-07-21 | Zentaris Ag | Compressed microparticles for dry injection |
AU2001249591A1 (en) | 2000-03-30 | 2001-10-15 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
DE10050199A1 (en) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation |
WO2002048141A1 (en) | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
ATE444060T1 (en) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS |
JO3429B1 (en) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
CA2465779A1 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
NZ538611A (en) | 2002-08-09 | 2007-03-30 | Janssen Pharmaceutica Nv | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US7497855B2 (en) | 2002-09-04 | 2009-03-03 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
ATE361059T1 (en) | 2002-11-08 | 2007-05-15 | Glaxo Group Ltd | ANTIVIRAL COMPOSITIONS |
CN100457754C (en) | 2002-11-15 | 2009-02-04 | 泰博特克药品有限公司 | Substituted indolepyridinium as anti-infective compounds |
WO2004050068A1 (en) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
CL2004000192A1 (en) | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | USE OF COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE TO PREPARE A MEDICINAL PRODUCT FOR THE PREVENTION OF HIV INFECTION SEXUAL RELATIONS OR AN INTIMATE COUPLE CONTACT. |
KR100629771B1 (en) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | Process for preparing oltipraz with diminished crystalline state or amorphous state |
WO2005123076A2 (en) | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
ME01246B (en) | 2004-09-02 | 2013-06-20 | Janssen Pharmaceutica Nv | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
WO2006024668A1 (en) | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
JP5324098B2 (en) | 2004-11-16 | 2013-10-23 | アルケルメス ファーマ アイルランド リミテッド | Injectable nanoparticulate olanzapine formulation |
TWI457136B (en) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Prevention of hiv-infection |
US20060269475A1 (en) | 2005-04-11 | 2006-11-30 | Ryu Wonhyoung | Multi-layer structure having a predetermined layer pattern including an agent |
TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
US20090142401A1 (en) | 2005-06-07 | 2009-06-04 | Leah Elizabeth Appel | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
EP1909762A2 (en) | 2005-07-28 | 2008-04-16 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
NZ569347A (en) | 2006-01-20 | 2011-07-29 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
EA021700B1 (en) | 2006-06-23 | 2015-08-31 | Тиботек Фармасьютикалз Лтд. | Pharmaceutical composition, comprising 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (tmc278) in the form of a suspension of micro- or nanoparticles, process for preparing same and use thereof for the long-term treatment or prophylaxis of hiv infection |
WO2008060360A2 (en) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Implantable medical device with apertures for delivery of bioactive agents |
TWI494133B (en) | 2007-03-14 | 2015-08-01 | Tibotec Pharm Ltd | Powders for reconstitution |
CA2693044C (en) | 2007-07-12 | 2017-03-14 | Tibotec Pharmaceuticals | Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
US20090123508A1 (en) | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
EP2358198A4 (en) | 2008-10-24 | 2012-11-14 | Concert Pharmaceuticals Inc | Hydroxyethylamino sulfonamide derivatives |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/en active Search and Examination
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/en active Active
- 2004-09-03 CA CA2537095A patent/CA2537095C/en active Active
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en active Application Filing
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en active Active
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/en unknown
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/en active Active
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en active Active
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/en active IP Right Grant
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/en active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/en active IP Right Maintenance
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en active Active
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/en not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/en active Active
- 2014-12-18 NO NO2014030C patent/NO2014030I1/en unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/en not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/en unknown
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/en unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/en unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/en active Active
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/en unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/en unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/en unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/en unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/en unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/en active Active
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/en unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/en unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/en unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I2/en unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/en active Active
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/en unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/en unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/en unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/en unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/en active
- 2016-12-20 CY CY2016048C patent/CY2016048I1/en unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/en unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2014030I1 (en) | (E) -4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile ("Rilpivirine") and any therapeutic form thereof as is covered by the relevant patent such as pharmaceutically acceptable salts of Rilpivirie including the hydrochloride salt of Rilpivirine, and emtricitabine. | |
NO2017065I1 (en) | Combination of rilpivirine hydrochloride or therapeutic equivalent thereof and tenofovir, especially tenofovir disproxil fumarate | |
HK1081527A1 (en) | Processes for the preparation of 4-[4-[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
CA2429263A1 (en) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia | |
CA2315141A1 (en) | Pharmaceutical compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof | |
PL1632232T3 (en) | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | |
WO2005037824A3 (en) | Method for the production of amino crotonyl compounds | |
WO2001068063A3 (en) | Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
UA92467C2 (en) | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile | |
AP2487A (en) | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile | |
SI1789139T1 (en) | Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile | |
WO2007024599A3 (en) | Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof | |
HRP20110563T1 (en) | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: JANSSEN SCIENCES IRELAND UC, IE |